Derek Dostal

Davis Polk advised the underwriters in connection with the $97.75 million initial public offering of 6,516,667 shares of common stock of Aprea Therapeutics, Inc., which includes 850,000…

Davis Polk advised the representatives and joint book-running managers of an SEC-registered offering by Black Hills Corporation of $400 million aggregate principal amount of its 3.050%…

Davis Polk advised the dealer managers in connection with a cash tender offer by Banc of California, Inc. for its depositary shares, each representing either a 1/40th ownership interest in…

Davis Polk advised IHS Markit Ltd. in connection with its SEC-registered offering of an additional $350 million aggregate principal amount of its 4.250% senior notes due 2029. The…

Davis Polk advised the underwriters in connection with the SEC-registered offering of 5,750,000 shares of common stock of Stemline Therapeutics, Inc. for total gross proceeds of…

Davis Polk advised Silver Spike Acquisition Corp. on its $250 million initial public offering of 25,000,000 units. Each unit had an initial offering price of $10 and consists of one Class A…

Davis Polk advised the underwriters in connection with the debut SEC-registered notes offering by Las Vegas Sands Corp. of $1.75 billion of its 3.200% senior notes due 2024, $1 billion…

Davis Polk advised the sole dealer manager in connection with a cash tender offer by Genesis Purchaser, LLC, an indirect subsidiary of NextEra Energy Partners, LP, for all of Genesis Solar…

Davis Polk advised the underwriters in connection with the $35 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd. The ordinary shares are listed on the Nasdaq…

Davis Polk advised the initial purchasers in connection with a Rule 144A/Regulation S offering by Stericycle, Inc. of $600 million aggregate principal amount of its 5.375% senior notes due…